^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STRN-NTRK2 fusion

    i
    Other names: NTRK2, TRKB, Neurotrophic tyrosine kinase, receptor, type 2, STRN, Striatin, Protein Phosphatase 2 Regulatory Subunit B'''Alpha, Striatin Calmodulin Binding Protein, Striatin Calmodulin-Binding Protein, PPP2R6A, SG2NA, STRN1
    Entrez ID:
    4915; 6801
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    1year
    Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy. (PubMed, Diagn Pathol)
    In conclusion, the identification of NTRK2 fusions in patients with soft tissue tumors could significantly improve the clinical outcome through selective NTRK inhibitor therapy, especially in the first-line setting. Prompt RNA-based NGS testing at initial diagnosis may benefit these patients. Our case is among the first few in the literature on NTRK2 fusion sarcoma with first-line larotrectinib therapy in the primary and metastatic setting, with good clinical response and minimal side effects.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STRN (Striatin) • NTRK (Neurotrophic receptor tyrosine kinase) • STAT6 (Signal transducer and activator of transcription 6)
    |
    NTRK1 fusion • NTRK2 fusion • STRN-NTRK2 fusion • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)